http://www.pharmabiz.com/interv/intrv46.asp
'Stem cell technology has the potential to revolutionize biomedical
research'
Dr. V K Vinayak, Advisor (Medical), the department of biotechnology,
Government of India, is the recipient of 13 national awards for excellence
in scientific research. Leading bodies like the Medical Council of India,
the Indian Council of Medical Research and the National Academy of Medical
Sciences have bestowed laurels upon him for his singular achievements. He
has produced over 230 papers of which as many as 130 have appeared in
leading international journals. He has had an important role in
policy-making too, thanks to his induction into many scientific and
administrative committees set up by the government. In an interview with K G
Narendranath of Pharmabiz.com, Dr Vinayak speaks about the accomplishments
of DBT in medical biotechnology with a thrust on novel areas like stem cell
technology and molecular medicine. -- Excerpts:
The consumption demand for biotechnology-driven pharmaceutical products is
increasing all over the world and more so, in developing countries like
India. Molecular medicine and stem cell technology are perceived to be areas
where substantive progress can be made in India in the years to come.
Doesn't the DBT look at these areas seriously?
Stem cell technology has the potential to revolutionize biomedical research
in the world. Already, there are interesting reports on this from countries
like the US. DBT is keen to seize the initiative on stem cells and we are
soon launching a joint venture project involving many agencies including the
industry for developing domestic expertise and facilities in the area. The
aim of the project is to use stem cells for tissue regeneration and thereby
find a credible remedy to degenerative diseases.
The project would entail substantive investment commitments from both the
government and the Indian biotech industry and institutions. A comprehensive
training programme for Indian biomedical researchers will be part of the
project. A nationwide network of biotech industries R&D setups and
government sector research bodies will take this ambitious project forward.
The department is seeking the concurrence of other wings of government like
the department of industry, and the expenditure department for this.
The project would be executed in coordination with prominent organizations
like the All India Institute of Medical Sciences, New Delhi, the Institute
of Immuno-heamatology, Mumbai, the Cancer Research Institute, Mumbai and the
National Center for Cell Sciences, Pune. These centers preserve bone marrow
cells, which contain substantial population of unprogrammed stem cells.
Major biotech industries in India are also being talked to, with intent to
expand the project parameters.
As undifferentiated cells, stem cells can show up as any organ cell. That
means, with the inducement of any particular gene, the properties of any
given organ cell could be engendered in the stem cells. We intend to draw an
initial financial support of Rs 20 crore from the government side, and
supplement it with sizeable funds expected from the private companies and
institutes. The two-pronged strategy we have drawn up emphasizes on
developing the expertise for growing the stem cells in test tube, and
preserving them un-proliferating. Preservation technology is crucial because
when stem cells multiply as they naturally do, they get differentiated and
forego the ability to adapt. Although some work has been done in the area in
India, overall, the efforts have been sketchy and objectives undefined. The
preservation of bone marrow the above centers is currently aimed to treat
blood-related disorders. Some of these centers have actually been getting
the financial support of DBT for the storage technologies called
cryo-preservation.
However, recent research in the US has shown that both embryonic and adult
stem cells could be used for developing certain cells/ organs used for
transplantation. The technology has hence obvious, proven applications in
the treatment of many major diseases such as diabetes, heomopoeisis and
heart muscle debilitation. Neuro-degenerative disorders like Parkinson
disease; Huntington disease could also be treated by stem cell -induced
tissue regeneration. Artificial bone development is another major area where
stem cell technology holds revolutionary potential. Future of biomedical
science is entirely dependent on understanding of stem cells and clinical
use. However, ethical issues that may come up regarding the clinical use of
stem cells would have to be taken care of.
What about the molecular medicines using recombinant technology?
For molecular medicines such as recombinant therapeutic proteins, the
domestic demand will grow manifold in a few years. A host of projects are in
progress in these areas.
The projects are aiming at development of important products such as
insulin, cytokines, growth factors, thrombolytic agents and erythropoietic
substances. A few domestic companies are already into indigenous commercial
production of recombinant hepatitis -B vaccines. This is at a time when both
genetically engineered and human plasma -derived hepatitis B vaccines are
being imported.
There are safety issues involved in the use of recombinant technology. The
regulatory procedure for products derived from recombinant technology needs
to be streamlined and eased. An expert committee has already prepared a set
of guidelines for this and they are being implemented. Also, a separate
regulatory body for clearance of recombinant products will be in place soon.
In a populous country like India, vaccination is seen to be an effective way
to control the spread of communicable diseases. What are the recent
achievements of DBT in this area?
In addition to recombinant vaccines for hepatitis B, vaccine research
dependent on other technologies are also in progress and has given
satisfactory results. We give importance to new technologies for vaccine
development. The government's Expanded Programme of Immunization has to
cater to about 23 million newborns against major childhood diseases and an
equal number of pregnant women against tetanus. Sufficient capacities have
already been created in the country for the production of vaccine against
tetanus, diphtheria, pertussis, BCG and measles. Polio vaccine bulk is now
being imported blended and used.
A rabies vaccine candidate has already been transferred to the industry and
the commercial production will start shortly. Besides, research is on to
develop an alternate for BCG. HIV vaccine research targeted at virus subtype
C that is largely found in India is also progressing. The National Cell
Science Centre, Pune in collaboration with Delhi University is working on a
DNA vaccine for tuberculosis. Vital research leads have already been
developed.
The Drug Controller General of India has recently given the nod for clinical
trials on a candidate vaccine against rotavirus developed jointly by the
Indian Institute of Science, Bangalore and the All India Institute of
Medical Sciences, New Delhi. With the global a market for the vaccine
estimated to be worth more than a billion dollars, the candidate vaccine is
perceived to be generating a lot of interest in the domestic pharmaceutical
industry. Rotavirus, which causes diarrhea in children, is the primary
reason for infant mortality in the world; international research focus has
long been on finding a rotavirus vaccine with variants of the virus being
detected even in developed countries like the US. The candidate vaccine is a
product of the India-US Vaccine Action Programme. Already, a host of
US-based research bodies, tied up to the Indo- US Vaccine Action Programme,
have completed the phase one study on an innocuous viral strain developed
under the collaborative project between the two countries. This strain would
be put in phase two trials in the US soon.
What is your forecast on the growth in demand for biotech products in India?
How much investment will be required in the next five years to create a
commensurate R&D and production base?
The great advances in the field of biotechnology in the world have had an
overwhelming impact on agriculture and health sectors particularly on the
pharmaceutical sector. Though there are diverse applications of
biotechnology benefiting all these areas, biotechnology-driven healthcare
products will dominate the scene. This sector is likely to constitute about
40 per cent of the biotech products consumption market by 2005.
As per an estimate made in 1997, this was 37 per cent. In the healthcare
sector, new investment opportunities exist in the production of cocktail
vaccines of DPT with hepatitis-B, hepatitis-A with -B, influenza, vericella
and meningitis vaccines. At the same time, if vaccines for hepatitis-E, -C,
HIV, and malaria become available globally, on which major breakthroughs
have been reported from abroad and in India, the demand for the products
will increase in India. Besides, there is also an unmet demand for several
animal and poultry vaccines of viral, bacterial and parasitic infections.
Most of the diagnostic products developed by immunological and PCR methods
such as those for the detection of viral diseases and tuberculosis are
currently being imported. In these areas, there is scope for setting up
local production facilities.